Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis and consumer packaged goods (CPG) company. The Company delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space. Its CPG portfolio includes gourmet wellness products by Martha Stewart CBD, and vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution, and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a diverse range of cannabis, hemp, and cannabis products in Canada. Its Rest-of-world cannabis segment includes the production, distribution, and sale of a diverse range of cannabis and hemp products internationally. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers.


TSX:WEED - Post by User

Post by lionshareon Apr 18, 2024 7:21pm
111 Views
Post# 35997028

Federal Drug Official ‘Adamantly Opposes’ Marijuana

Federal Drug Official ‘Adamantly Opposes’ MarijuanaGood luck! if your company is waiting for change? Keep waiting!

Certain DEA officials are reportedly resisting the Biden administration’s rescheduling push, disputing the HHS findings on marijuana’s safety profile and medical potential, according to unnamed sources who spoke with The Wall Street Journal.


GOP Congressman Claims Top Federal Drug Official ‘Adamantly Opposes’ Marijuana Rescheduling, But Agency Endorsed FDA Recommendation - Read of Green
<< Previous
Bullboard Posts
Next >>